Cell lines

HeLa cells

Preparation method

The solubility of this compound in DMSO is >10.3 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

25 μg/ml, 30 min

Applications

Cordycepin (25 μg/ml) suppressed the labeling of messenger RNA in HeLa cells. Cordycepin inhibited NO production in a dose-dependent manner up to 30 μg/ml. In RAW 264.7 cells, treatment with cordycepin decreased LPS-induced synthesis of iNOS protein in a dose-dependent manner. Cordycepin significantly decreased the mRNA levels of TNF-α induced by LPS in a dose-dependent manner. Cordycepin (20 μg/ml) inhibited LPS-mediated IκBα phosphorylation in a dose-dependent manner in LPS-induced macrophage cell. Cordycepin decreased the phosphorylation level of p38 and Akt in LPS-stimulated cells in a concentration-dependent manner.

Animal models

Mice bearing B16 melanoma (B16-BL6) cells,

Dosage form

Oral administration, 15 mg/kg per day for 2 weeks

Application

Oral administration of cordycepin (15 mg/kg per day) for 2 weeks significantly reduced the wet weight of the primary tumour lump, without any loss of bodyweight or systemic toxicity. Cordycepin (15 mg/kg per day) inhibited the tumour enlargement in the right thigh inoculated with B16-BL6 cells premixed with extracellular matrix. In hematogenic metastatic mouse model bearing B16-BL6 melanoma cells, 3-hour exposure to various concentrations of cordycepin (0.3, 1 and 3 μg/ml) dose-dependently reduced the number of nodules formed in lung at 15 days after the tumor injection. Cordycepin did not influence the growth curve of B16-BL6 cells at concentrations up to 3 μg/ml.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Cordycepin, which is a nucleoside derivative isolated from Cordyceps, inhibits IL-1β-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts (RASFs) in a dose-dependent manner.

Cordycepin is a potent inhibitor of IL-1β-induced chemokine production and MMP expression and strongly blocks the p38/JNK/AP-1 signalling pathway in RASFs. The effect of Cordycepin on cellular toxicity of RASFs is assessed using MTT assay. Treatment of RASFs with Cordycepin (50 μM or 100 μM) for 24 h does not cause any significant change in cell viability. However, cell viability is slightly decreased when cells are incubated with 100 μM Cordycepin for 48 h[1].

References:
[1]. Noh EM, et al. Cordycepin inhibits IL-1beta-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts. Rheumatology (Oxford). 2009 Jan;48(1):45-8.